Form 4: Surrozen CFO Maleki Granted 50,000 Stock Options

Surrozen, Inc.'s Chief Financial Officer, Andrew Pedrum Maleki, was granted 50,000 employee stock options with an exercise price of $12.94.

Summary

• Andrew Pedrum Maleki, Chief Financial Officer of Surrozen, Inc. (SRZN), was granted 50,000 employee stock options.
• The options have an exercise price of $12.94 per share.
• The transaction date for this grant is listed as November 12, 2025.
• The vesting schedule stipulates that 25% of the shares subject to the option vest on the first anniversary of the vesting commencement date, with the remaining 75% vesting in 36 equal monthly installments thereafter for the following three years.
• Vesting is contingent upon the reporting person's continuous service through the applicable vesting date.
• The options are set to expire on November 11, 2035.

Sentiment

Score: 6

Explanation: The filing reports a standard executive compensation event (stock option grant), which is generally positive for aligning management incentives but does not provide new operational or financial performance data. The unusual future transaction date introduces a minor ambiguity, but the core event is routine.

Positives

• The stock option grant aligns the Chief Financial Officer's long-term financial interests with those of shareholders, incentivizing sustained company performance.
• The multi-year vesting schedule promotes executive retention and commitment to the company's strategic objectives and growth.

Negatives

• Potential future dilution for existing shareholders if the options are exercised, although this is a standard component of executive compensation plans.

Risks

• The value of the stock options is directly tied to the future market price of Surrozen, Inc. common stock, which is subject to market volatility and company performance.
• Vesting is contingent on continuous service, meaning the options could be forfeited if the reporting person's employment terminates before the vesting conditions are met.
• The reported transaction date of November 12, 2025, is in the future relative to the filing date of November 13, 2025, which is an unusual occurrence for a Form 4 filing that typically reports completed transactions, potentially indicating a clerical error or a pre-arranged future grant not explicitly marked under Rule 10b5-1(c).

Future Outlook

The vesting schedule for the granted options indicates a future commitment from the CFO, with 25% vesting on the first anniversary of the commencement date and the remainder vesting monthly over the subsequent three years, contingent on continuous service.

Industry Context

Granting stock options to key executives like the Chief Financial Officer is a common and established practice across publicly traded companies, particularly in growth-oriented sectors such as biotechnology. This strategy is widely used to attract, retain, and motivate top talent, while also aligning executive incentives with the long-term creation of shareholder value.

Comparison to Industry Standards

• The grant of stock options to a Chief Financial Officer is a standard component of executive compensation packages across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule, featuring an initial cliff followed by monthly installments over several years, is typical for long-term incentive plans designed to promote executive retention and sustained performance, comparable to practices observed at other emerging biotech firms.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefits from increased alignment of management's interests with long-term shareholder value creation and executive retention.
• Employees: Standard executive compensation practices can set a precedent or expectation for other key personnel within the company.

Next Steps

• The granted options will begin to vest according to the specified schedule, contingent on the CFO's continuous service through the applicable vesting dates.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (stock option grant) and does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It primarily serves as a disclosure of insider activity, which is generally expected for executive retention and alignment, despite the unusual future transaction date.

Keywords

Surrozen Inc., SRZN, Andrew Pedrum Maleki, CFO, Stock Options, Employee Stock Option, Executive Compensation, Form 4, Beneficial Ownership